Showing 1 - 10 of 38
I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I examine the effect of the vintage of prescription drugs (and other variables) on the life expectancy and age-adjusted mortality rates of residents of Germany, using...
Persistent link: https://www.econbiz.de/10003977959
Persistent link: https://www.econbiz.de/10001619498
Between 1960 and 1997, life expectancy at birth of Americans increased approximately 10% - from 69,7 to 76,5 years - and it has been estimated that the value of life extension during this period nearly equaled the gains in tangible consumption. While life expectancy has tended to increase, there...
Persistent link: https://www.econbiz.de/10001566397
Persistent link: https://www.econbiz.de/10001695895
Persistent link: https://www.econbiz.de/10000651512
Persistent link: https://www.econbiz.de/10001719206
Persistent link: https://www.econbiz.de/10001646748
Persistent link: https://www.econbiz.de/10002218410
In this paper, we address the issue of spurious correlation in the production of health in a systematic way. Spurious correlation entails the risk of linking health status to medical (and nonmedical) inputs when no links exist. This note first presents the bounds testing procedure as a method to...
Persistent link: https://www.econbiz.de/10014046543
We develop a simple theoretical model of the allocation of public biomedical research expenditure, and present some empirical evidence about the determinants of this allocation. The structure of expenditure should depend on the relative costs as well as the relative benefits of different kinds...
Persistent link: https://www.econbiz.de/10013219295